Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

BACKGROUND: CRC is a significant cause of cancer mortality, and new therapies are needed for patients with advanced disease. TAK-733 is a highly potent and selective investigational novel MEK allosteric site inhibitor. MATERIALS AND METHODS: In a preclinical study of TAK-733, a panel of CRC cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lieu, Christopher H., Klauck, Peter J., Henthorn, Patrick K., Tentler, John J., Tan, Aik-Choon, Spreafico, Anna, Selby, Heather M., Britt, Blair C., Bagby, Stacey M., Arcaroli, John J., Messersmith, Wells A., Pitts, Todd M., Eckhardt, S. Gail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741473/
https://www.ncbi.nlm.nih.gov/pubmed/26439693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741473/
https://www.ncbi.nlm.nih.gov/pubmed/26439693

Ejemplares similares